Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01996267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

Study acronym: TRAIN-2
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv17
  2. Completion date: Dec 2024 to Dec 2030v16
  3. Re-verified, no change to tracked fieldsv15
  4. Completion date: Dec 2022 to Dec 2024v14
  5. 3 versions Re-verified since Jul 8, 2020, no change to tracked fieldsv11-v13
Show 9 earlier versionsHide 9 earlier versions
  1. Completion date: Dec 2019 to Dec 2022v10
  2. Re-verified, no change to tracked fieldsv9
  3. Trial status: Recruiting to Active, Not Recruiting Site details revised at 33 of 33 sitesv8 Show 1 more changeShow less
    • Site details revised at 33 of 33 sites
  4. Site details revised at 7 of 33 sitesv7
  5. Site details revised at 16 of 33 sitesv6
  6. Study sites: 32 to 33v5
  7. Site details revised at 1 of 32 sites Collaborators revised (2)v4 Show 1 more changeShow less
    • Collaborators revised (2)

    See this version in full on ClinicalTrials.gov ↗

  8. Interventions: FEC+Pertuzumab (Drug), PTC+Pertuzumab (Drug) to FEC-T+Pertuzumab (Drug), PTC+Pertuzumab (Drug) Collaborators: 1 to 2v3 Show 1 more changeShow less
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  9. Trial status: Not Yet Recruiting to Recruiting Start date: Nov 2013 to Dec 2013 · Site details revised at 32 of 32 sitesv2 Show 2 more changesShow less
    • Start date: Nov 2013 to Dec 2013
    • Site details revised at 32 of 32 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
Trial Details
NCT Number NCT01996267
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Roche Pharma AG, Borstkanker Onderzoek Groep
Conditions Breast Cancer, HER2 Positive
Enrollment 437 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov